IQVIA (NYSE:IQV) Earns Overweight Rating from Analysts at Stephens

Investment analysts at Stephens began coverage on shares of IQVIA (NYSE:IQV) in a research report issued to clients and investors on Friday,Briefing.com Automated Import reports. The brokerage set an “overweight” rating and a $250.00 price target on the medical research company’s stock. Stephens’ price target indicates a potential upside of 30.53% from the stock’s current price.

A number of other brokerages have also commented on IQV. Redburn Atlantic assumed coverage on IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 target price for the company. Barclays decreased their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Robert W. Baird cut their target price on IQVIA from $213.00 to $212.00 and set a “neutral” rating on the stock in a report on Wednesday, December 11th. Bank of America decreased their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Finally, The Goldman Sachs Group dropped their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $255.82.

IQVIA Trading Up 0.3 %

NYSE:IQV opened at $191.52 on Friday. IQVIA has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock has a market capitalization of $34.76 billion, a price-to-earnings ratio of 25.13, a PEG ratio of 2.05 and a beta of 1.49. The firm has a fifty day simple moving average of $209.54 and a two-hundred day simple moving average of $223.42.

Hedge Funds Weigh In On IQVIA

Several institutional investors have recently added to or reduced their stakes in IQV. Capital Performance Advisors LLP purchased a new position in IQVIA in the third quarter valued at about $27,000. Park Place Capital Corp bought a new stake in shares of IQVIA in the 3rd quarter worth approximately $28,000. Itau Unibanco Holding S.A. purchased a new position in IQVIA in the second quarter valued at approximately $29,000. International Assets Investment Management LLC bought a new position in IQVIA during the second quarter valued at $32,000. Finally, Avior Wealth Management LLC raised its stake in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.